Literature DB >> 3057297

Prognostic significance of immunoglobulin isotype expression in B-cell non-Hodgkin's lymphoma.

C Lindemalm1, B Christensson, G Biberfeld, P Biberfeld, M Björkholm, B Johansson, E Kimby, H Mellstedt.   

Abstract

Lymph node biopsies from 170 patients with untreated non-Hodgkin's lymphomas (NHL) of B-cell type were immunophenotyped and analyzed for the Ig heavy and light chain isotypes and their relation to prognosis. IgM alone was more frequently seen in high grade (53%) compared to low grade (20%) NHL. In contrast, IgM/IgD isotypes were more frequent in low grade (47%) than in high grade NHL (20%). IgG or IgA heavy chain, alone or in combination with other heavy chain isotypes, were expressed with the same frequencies in both low (32%) and high (27%) grade NHL. Clonally restricted kappa light chain expression was noted in 64% of low grade and 66% of high grade NHL patients. Only in chronic lymphocytic leukemia (CLL) and immunocytoma (IC) was a shorter survival time noted for patients with tumors expressing IgG and/or IgA heavy chains compared to those expressing IgM or IgM/IgD (P less than 0.001). This difference was not seen as being low grade follicle center cell-derived (FCC) or high grade NHL. The expression of kappa light chains on the tumor cells was associated with a significantly longer survival in CLL and IC patients only (P less than 0.01).

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3057297     DOI: 10.1007/bf03003191

Source DB:  PubMed          Journal:  Med Oncol Tumor Pharmacother        ISSN: 0736-0118


  22 in total

Review 1.  Control of immunoglobulin class switch recombination.

Authors:  A Radbruch; C Burger; S Klein; W Müller
Journal:  Immunol Rev       Date:  1986-02       Impact factor: 12.988

2.  Human neoplastic B cells: monoclonal models of B-cell differentiation.

Authors:  T Kishimoto
Journal:  Immunol Today       Date:  1983-04

3.  Phenotypes in chronic B-lymphocytic leukemia probed by monoclonal antibodies and immunoglobulin secretion studies: identification of stages of maturation arrest and the relation to clinical findings.

Authors:  J Gordon; H Mellstedt; P Aman; P Biberfeld; M Björkholm; G Klein
Journal:  Blood       Date:  1983-10       Impact factor: 22.113

4.  Idiotype-bearing lymphoid cells in plasma cell neoplasia.

Authors:  H Mellstedt; G Holm; D Pettersson; D Peest
Journal:  Clin Haematol       Date:  1982-02

5.  Blood clonal B cell excess (CBE) at diagnosis in patients with non-Hodgkin lymphoma (NHL). Relation to clinical stage, histopathology and response to treatment.

Authors:  C Lindemalm; H Mellstedt; B Nilsson; P Biberfeld; M Björkholm; B Christensson; G Holm; B Johansson
Journal:  Eur J Cancer Clin Oncol       Date:  1987-06

Review 6.  The physiology of B cells as studied with tumor models.

Authors:  J M Hanley-Hyde; R G Lynch
Journal:  Annu Rev Immunol       Date:  1986       Impact factor: 28.527

7.  Lymphocyte subpopulations in chronic lymphocytic leukemia (CLL). Relation to the activity of the disease.

Authors:  H Mellstedt; D Pettersson; G Holm
Journal:  Acta Med Scand       Date:  1978

8.  Prognostic significance of receptors for the third component of complement an heavy chain phenotype in diffuse B-cell lymphomas.

Authors:  E J Gold; R H Mertelsmann; D A Filippa; T H Szatrowski; B Koziner; B Clarkson
Journal:  Blood       Date:  1983-07       Impact factor: 22.113

9.  Surface immunoglobulin pattern of the leukaemic cell population in chronic lymphocytic leukaemia (CLL) in relation to disease activity.

Authors:  E Kimby; H Mellstedt; M Björkholm; G Holm
Journal:  Hematol Oncol       Date:  1985 Oct-Dec       Impact factor: 5.271

10.  Induction of immunoglobulin isotype switching in cultured I.29 B lymphoma cells. Characterization of the accompanying rearrangements of heavy chain genes.

Authors:  J Stavnezer; S Sirlin; J Abbott
Journal:  J Exp Med       Date:  1985-03-01       Impact factor: 14.307

View more
  1 in total

1.  A two-gene signature, SKI and SLAMF1, predicts time-to-treatment in previously untreated patients with chronic lymphocytic leukemia.

Authors:  Carmen D Schweighofer; Kevin R Coombes; Lynn L Barron; Lixia Diao; Rachel J Newman; Alessandra Ferrajoli; Susan O'Brien; William G Wierda; Rajyalakshmi Luthra; L Jeffrey Medeiros; Michael J Keating; Lynne V Abruzzo
Journal:  PLoS One       Date:  2011-12-14       Impact factor: 3.240

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.